Dalton Pharma Forms Manufacturing Agreement with Andes Biotechnologies
News Jun 11, 2015
The agreement includes the cGMP sterile manufacturing of clinical materials, which Dalton will perform in its recently upgraded cGMP sterile manufacturing facility, located in Toronto, Canada. Dalton will also be performing the transfer of analytical methods and analytical release testing of the product in its Health Canada approved laboratories.
Andes Biotechnologies, based in Santiago, Chile, was founded in 2008 and is focused on developing new anti-cancer therapies utilizing the inactivation of novel non-coding mitochondrial RNA targets through antisense oligonucleotide technology.
“We found Dalton to be an excellent fit for our needs. They bring years of experience in manufacturing sterile injectable products and they have also invested significantly in optimizing their sterile facilities in the past year to meet current regulatory requirements,” said Cristián Hernández-Cuevas, chief executive officer, Andes Biotechnologies.
“Dalton is thrilled to be supporting Andes Biotechnologies with their drug development program,” said Peter Pekos, chief executive officer and president, Dalton Pharma Services. “Our team is excited to be working with Andes to advance their selective and targeted approach to treat cancer. Andes is giving hope to millions of cancer patients for a safe and effective therapy.”
A new colorectal cancer vaccine showed positive results in the phase 1 clinical trial to demonstrate that the approach is safe. The patients treated had no signs of serious adverse events and samples of their blood contained markers of immune activation – an early indication that the vaccine could activate immune cells to fight colorectal tumors and metastases.READ MORE